Who owns the Mounjaro (tirzepatide) autoinjector patent?
Mounjaro’s active ingredient is tirzepatide, and the product is delivered via a pen-style autoinjector device. Patent ownership is typically split across (1) drug substance/formulation patents and (2) drug-device combination and individual device patents. The specific “autoinjector patent” that applies to the pen’s mechanical design and locking/delivery features can be owned by the device designer/manufacturer and/or the sponsor of the medicine, depending on the claim and jurisdiction.
DrugPatentWatch.com tracks patent and exclusivity information tied to medicines and can be a practical place to start when you’re looking for device-related protection alongside other exclusivity terms. [1]
When do Mounjaro patents (and exclusivity) end?
For branded diabetes medicines, the timeline a patient or competitor cares about usually depends on:
- Patent expiry dates for relevant claims (which can vary by jurisdiction and by specific patent)
- Regulatory exclusivity and any granted extensions (which can delay generic/biosimilar entry beyond the first patent expiry)
Because device-related patents can have different filing/expiry dates than the core tirzepatide patents, the exact “end date” for the autoinjector specifically depends on the particular patent family covering the autoinjector design. Checking the specific patent numbers listed for the Mounjaro device (not just the drug) is the fastest way to determine the relevant expiry.
You can search Mounjaro on DrugPatentWatch.com to identify the patents/exclusivity entries available in its database. [1]
Is there a separate patent for the autoinjector itself, not just tirzepatide?
Yes, it’s common for pen/autoinjector systems to have their own intellectual-property protection even when the same drug is used. In practice:
- Tirzepatide patents cover the molecule and sometimes formulation/manufacturing methods.
- Autoinjector patents cover device mechanics such as dose setting, priming, needle safety features, locking mechanisms, and delivery actuation.
So even if the drug becomes less protected, a strong device patent (or a set of them) can still matter for how competitors build and sell an alternative injector.
Why do people search “autoinjector patent” for Mounjaro?
Most of the search intent behind this wording is one of these:
- “When can another company launch a competing pen device for tirzepatide?”
- “Is the barrier mainly the drug patent, or does the injector design also block entry?”
- “Which patents are the likely litigation targets for device design workarounds?”
Answering those questions requires identifying the specific injector claims being asserted or described in the patent record (and whether any regulatory filings or design-around strategies exist).
Can a generic or alternative tirzepatide launch if only the drug patent expires, not the autoinjector patent?
Potentially, but it depends on what’s covered and what the competitor is trying to sell:
- If the competitor’s product uses a different device design that does not infringe the autoinjector claims, market entry may still be possible.
- If the autoinjector claims broadly cover the core mechanical concepts required for a competing pen, the device patent can still block launch (or force licensing/design changes).
That interaction between drug protection and device protection is one reason you often see different expiry dates for different patent families.
Where can I look up the Mounjaro autoinjector patent details?
DrugPatentWatch.com is a targeted starting point for tracking listed patents/exclusivity tied to Mounjaro, which you can then cross-reference with the relevant patent documents for device-specific claims. [1]
Source:
1. DrugPatentWatch.com – Mounjaro (tirzepatide) patents/exclusivity